Online inquiry

IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ535MR)

This product GTTS-WQ535MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Psoriasis, Organ transplant immunological rejection suppression research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ535MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1487MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ4801MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ11244MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ15049MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ1258MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ173MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ14632MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ2382MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW